We have located links that may give you full text access.
Case Reports
Journal Article
GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report.
Medicine (Baltimore) 2021 December 24
INTRODUCTION: The optimal management of recurrent ovarian granulosa cell tumors is still unknown, and hormone therapy may be an alternative for chemotherapy-resistant cases.
PATIENT CONCERNS: A 46-year-old woman presented with a third recurrence after primary treatment of granulosa cell tumors. She developed tumor progression and drug-induced nephritis after 6 cycles of combined treatment with cisplatin and paclitaxel for the second recurrence and failed to benefit from chemotherapy, after the third optimal cytoreduction and tumor progression after 6 months of letrozole treatment.
DIAGNOSIS: Letrozole-resistant recurrent ovarian granulosa cell tumors.
INTERVENTIONS: Intramuscular Diphereline 3.75 mg q28d.
OUTCOMES: Computed tomography showed the metastatic neoplasm resolved. Progression-free survival is 20 months.
CONCLUSION: Hormone therapy may be an alternative to treat recurrent granulosa cell tumors, and gonadotropin-releasing hormone agonists may be a rescue treatment for aromatase inhibitor-resistant cases.
PATIENT CONCERNS: A 46-year-old woman presented with a third recurrence after primary treatment of granulosa cell tumors. She developed tumor progression and drug-induced nephritis after 6 cycles of combined treatment with cisplatin and paclitaxel for the second recurrence and failed to benefit from chemotherapy, after the third optimal cytoreduction and tumor progression after 6 months of letrozole treatment.
DIAGNOSIS: Letrozole-resistant recurrent ovarian granulosa cell tumors.
INTERVENTIONS: Intramuscular Diphereline 3.75 mg q28d.
OUTCOMES: Computed tomography showed the metastatic neoplasm resolved. Progression-free survival is 20 months.
CONCLUSION: Hormone therapy may be an alternative to treat recurrent granulosa cell tumors, and gonadotropin-releasing hormone agonists may be a rescue treatment for aromatase inhibitor-resistant cases.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app